

## SODIUM ZIRCONIUM CYCLOSILICATE powder for oral suspension (Lokelma® ▼) for treating hyperkalaemia

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of SODIUM ZIRCONIUM CYCLOSILICATE powder for oral suspension (Lokelma® ▼) for treating hyperkalaemia**

### GREY

Sodium zirconium cyclosilicate is indicated for the treatment of hyperkalaemia in adult patients. It is a non-absorbed, non-polymer inorganic powder which lowers serum potassium levels and increases faecal potassium by capturing potassium throughout the gastrointestinal (GI) tract and reducing the concentration of free potassium in the GI lumen.<sup>1</sup>

This recommendation will be reviewed when the NICE TA is published. This is expected to be in August 2019.

In the meantime, prescribers should continue to follow current local Trust guidance on the management of hyperkalaemia and prescribe local Formulary choices.

- > Pan Mersey APC Formulary: [Potassium removal](#)

### References

1. AstraZeneca UK Limited. Summary of Product Characteristics. [Lokelma 10 g powder for oral suspension](#), 06 December 2018. Accessed online 16 May 2019.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.